04/09/2017 Guerbet reinforces its digital innovative strategy - Appointment of François Nicolas to the position of Chief Digital Officer

Guerbet is reinforcing its digital innovation strategy and announces the appointment of François Nicolas to the position of Chief Digital Officer (CDO).


17/08/2017 APCIO 2017: Guerbet actor in interventional oncology in the Asia Pacific region

APCIO 2017 │ from 25 to 27 August 2017 │ The Lalit │ New Delhi (India)


27/07/2017 Revenue at June 30, 2017: Satisfactory activity growth

Guerbet is publishing revenue of €407.1 million for the 1st half-year of 2017, up 8.1% at current exchange rates and 5.6% at constant exchange rates (CER). In the second quarter, published revenue stood at €204.0 million, up 5.7% at current exchange rates and 3.8% at CER.


10/07/2017 Guerbet announces plans to streamline its contrast media portfolio

Guerbet announced today that it will phase out sales throughout the world of two products: Hexabrix® (meglumine and sodium ioxaglate) and Optimark® (gadoversetamide).


22/06/2017 MLCTO 2017: Guerbet, a partner in the initiatives implemented for interventional cardiologists

MLCTO 2017 │ from June 29 to July 1 │ Hyatt Regency │ Palais de la Méditerranée │ Nice (France)


22/06/2017 APPLE 2017: Guerbet implicated in the fight against liver cancer

APPLE 2017 │ from July 14 to 16 │ Grand Copthorne Waterfront Hotel │ Singapore


14/06/2017 Guerbet invests in the Truffle Capital fund dedicated to medical devices and biotechnologies

Guerbet today announced that it has signed an equity acquisition of fifteen million Euros in the BioMedTech fund (FPCI) managed by Truffle Capital


Displaying results ###SPAN_BEGIN###%s to %s out of ###SPAN_BEGIN###%s